Phase 3 Hereditary Angioedema (HAE) Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.170 enrolled62 locationsNCT06679881
Recruiting
Phase 3
A Study of Navenibart in Participants With Hereditary Angioedema
Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.145 enrolled87 locationsNCT06842823
Recruiting
Phase 3
Donidalorsen Treatment in Children With Hereditary Angioedema
Hereditary Angioedema (HAE)
Ionis Pharmaceuticals, Inc.20 enrolled6 locationsNCT07298447
Recruiting
Phase 3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled48 locationsNCT07428499